Corcept Therapeutics
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments fo...
Latest News
16 hours ago · gurufocus.com
ESMO Rare Cancers Publishes Case Report Detailing Eight-Year Response to Relacorilant Plus Nab-Paclitaxel in Metastatic Vulvar CancerCorcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinolo
13 days ago · zacks.com
CORT's Q3 Earnings Beat, Higher Product Sales Aid Y/Y RevenuesCorcept's Q3 earnings and revenues beat estimates, driven by strong Lifyorli uptake and higher Korlym sales, as the company advances its pipeline.
13 days ago · seekingalpha.com
Corcept Therapeutics Incorporated (CORT) Q3 2026 Earnings Call TranscriptCorcept Therapeutics Incorporated (CORT) Q3 2026 Earnings Call Transcript
13 days ago · marketbeat.com
Corcept Therapeutics Q3 Earnings Call HighlightsCorcept Therapeutics NASDAQ: CORT reported third-quarter 2026 revenue of $340.5 million, up 33% from the prior quarter and 64% from a year earlier, as growth in its endocrinology business and the launch of ovarian cancer treatment Lifyorli lifted results.
13 days ago · zacks.com
Corcept Therapeutics (CORT) Q3 Earnings and Revenues Surpass EstimatesCorcept Therapeutics (CORT) came out with quarterly earnings of $1.01 per share, beating the Zacks Consensus Estimate of $0.68 per share. This compares to earnings of $0.16 per share a year ago.
29 days ago · zacks.com
Can Lifyorli Aid Corcept's Long-Term Growth Prospects Beyond Korlym?CORT banks on newly approved drug, Lifyorli, while potential new approvals and clinical studies could help diversify revenues beyond Korlym.
2 months ago · businesswire.com
Corcept Announces Planned Leadership TransitionREDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced the retirement of Sean Maduck, President of the company's Endocrinology division. Justin Gunn will succeed Mr. Maduck and will fully assume his new responsibilities starting October.
2 months ago · zacks.com
CHMP Backs CORT's Lifyorli Combo in Platinum-Resistant Ovarian CancerCorcept's Lifyorli plus nab-paclitaxel wins a positive CHMP opinion for platinum-resistant ovarian cancer, with an EC decision expected in Q4 2026.
2 months ago · businesswire.com
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined wit.
2 months ago · zacks.com
Will Korlym Continue to Aid CORT's Growth Through the Rest of 2026?Corcept's Korlym sales rise 6.2% in H1 2026 as demand grows, while Lifyorli's launch offers a path to diversify revenues.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove CORT